JP2008515990A5 - - Google Patents

Download PDF

Info

Publication number
JP2008515990A5
JP2008515990A5 JP2007536865A JP2007536865A JP2008515990A5 JP 2008515990 A5 JP2008515990 A5 JP 2008515990A5 JP 2007536865 A JP2007536865 A JP 2007536865A JP 2007536865 A JP2007536865 A JP 2007536865A JP 2008515990 A5 JP2008515990 A5 JP 2008515990A5
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
cancer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007536865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515990A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/036761 external-priority patent/WO2006044502A2/en
Publication of JP2008515990A publication Critical patent/JP2008515990A/ja
Publication of JP2008515990A5 publication Critical patent/JP2008515990A5/ja
Pending legal-status Critical Current

Links

JP2007536865A 2004-10-13 2005-10-13 ナンセンス抑制のための化合物およびその使用方法 Pending JP2008515990A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US61763304P 2004-10-13 2004-10-13
US61763404P 2004-10-13 2004-10-13
US61765504P 2004-10-13 2004-10-13
US61765304P 2004-10-13 2004-10-13
US61767004P 2004-10-13 2004-10-13
US62417004P 2004-11-03 2004-11-03
PCT/US2005/036761 WO2006044502A2 (en) 2004-10-13 2005-10-13 Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases

Publications (2)

Publication Number Publication Date
JP2008515990A JP2008515990A (ja) 2008-05-15
JP2008515990A5 true JP2008515990A5 (cg-RX-API-DMAC10.html) 2008-12-11

Family

ID=35517967

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007536867A Pending JP2008515992A (ja) 2004-10-13 2005-10-13 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
JP2007536837A Pending JP2008515985A (ja) 2004-10-13 2005-10-13 ナンセンス抑制の化合物とその使用方法
JP2007536865A Pending JP2008515990A (ja) 2004-10-13 2005-10-13 ナンセンス抑制のための化合物およびその使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007536867A Pending JP2008515992A (ja) 2004-10-13 2005-10-13 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
JP2007536837A Pending JP2008515985A (ja) 2004-10-13 2005-10-13 ナンセンス抑制の化合物とその使用方法

Country Status (11)

Country Link
US (10) US9051342B2 (cg-RX-API-DMAC10.html)
EP (13) EP2363129A1 (cg-RX-API-DMAC10.html)
JP (3) JP2008515992A (cg-RX-API-DMAC10.html)
KR (3) KR20070065429A (cg-RX-API-DMAC10.html)
AU (3) AU2005295730A1 (cg-RX-API-DMAC10.html)
BR (2) BRPI0515995A (cg-RX-API-DMAC10.html)
CA (5) CA2582885A1 (cg-RX-API-DMAC10.html)
IL (3) IL182459A0 (cg-RX-API-DMAC10.html)
MX (3) MX2007004479A (cg-RX-API-DMAC10.html)
SG (2) SG156640A1 (cg-RX-API-DMAC10.html)
WO (5) WO2006044502A2 (cg-RX-API-DMAC10.html)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003252136A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
JP2008515992A (ja) * 2004-10-13 2008-05-15 ピーティーシー セラピューティクス,インコーポレーテッド 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
EP1940801A2 (en) * 2005-10-14 2008-07-09 NeuroSearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
WO2007047706A2 (en) * 2005-10-17 2007-04-26 Children's Hospital Methods and compositions for regulating gene expression
BRPI0707719A2 (pt) 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
EP2387995A1 (en) 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
JP5420395B2 (ja) 2006-04-07 2014-02-19 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセット輸送体の調節剤
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
UA99600C2 (en) * 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
KR100858357B1 (ko) * 2006-10-02 2008-09-11 (주) 디지탈바이오텍 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008157407A2 (en) * 2007-06-13 2008-12-24 University Of Virginia Patent Foundation Thiadiazole, oxadiazole and triazole derivatives for treating leukemia
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
CN102743385B (zh) 2007-11-16 2014-09-17 沃泰克斯药物股份有限公司 Atp结合盒转运蛋白的异喹啉调节剂
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
JP5369854B2 (ja) 2008-04-21 2013-12-18 住友化学株式会社 有害節足動物防除組成物および縮合複素環化合物
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
WO2010008831A2 (en) * 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
US9126938B2 (en) 2009-08-17 2015-09-08 The Brigham And Women's Hospital, Inc. Phosphatidylcholine transfer protein inhibitors
CN102573478B (zh) 2009-10-12 2015-12-16 拜尔农作物科学股份公司 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑
US20130040983A1 (en) * 2010-01-08 2013-02-14 Jean-Michel Vernier Raf kinase inhibitors
EP2563778B1 (en) 2010-03-25 2016-08-24 Vertex Pharmaceuticals Incorporated Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
TWI549950B (zh) 2010-04-07 2016-09-21 維泰克斯製藥公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2013536231A (ja) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド (r)−1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)−n−(1−(2,3−ジヒドロキシプロピル)−6−フルオロ−2−(1−ヒドロキシ−2−メチルプロパン−2−イル)−1h−インドール−5−イル)シクロプロパンカルボキサミドを含む医薬組成物およびその投与
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
KR101452235B1 (ko) * 2012-02-03 2014-10-22 서울대학교산학협력단 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 rage 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
WO2013181232A2 (en) 2012-05-29 2013-12-05 Michael Ross Johnson Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
KR102396897B1 (ko) 2012-11-02 2022-05-13 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환의 치료를 위한 약제학적 조성물
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
WO2014163934A1 (en) * 2013-03-13 2014-10-09 Dow Agrosciences Llc Preparation of 1,3-(substituted-diaryl)-1,2,4-triazoles
CA2903103C (en) * 2013-03-15 2020-06-09 Discoverybiomed, Inc. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
HK1218537A1 (zh) 2013-03-15 2017-02-24 Discoverybiomed Inc. 香豆素衍生物以及用於治疗过度增生性疾病的方法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2657989T3 (es) * 2013-03-15 2018-03-07 Monsanto Technology Llc Azoles n-, c-disustituidos para controlar plagas de nematodos
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
FR3011468B1 (fr) * 2013-10-04 2015-12-04 Inventiva Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
WO2015054283A1 (en) * 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
HK1245246A1 (zh) 2014-12-01 2018-08-24 恒翼生物医药科技(上海)有限公司 作为溴域抑制剂的取代吡啶酮
CN107207488B (zh) * 2014-12-17 2020-11-17 伦敦皇家学院 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物
US10647688B2 (en) * 2014-12-19 2020-05-12 Galderma Research & Development Compounds, synthesis method thereof and use of same in medicine and in cosmetics
WO2016105491A1 (en) 2014-12-23 2016-06-30 Fgh Biotech Compositions of fatostatin based heterocyclic compounds and uses thereof
ES2895729T3 (es) * 2015-07-24 2022-02-22 Syngenta Participations Ag Derivados de 1,2,4-triazol activos como plaguicidas con sustituyentes con contenido en azufre
TW201729807A (zh) 2015-10-30 2017-09-01 Ptc治療公司 用於治療癲癇的方法
WO2017108569A1 (en) 2015-12-22 2017-06-29 Syngenta Participations Ag Pesticidally active pyrazole derivatives
CA3048202A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
US11497738B2 (en) 2016-04-29 2022-11-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
WO2017205503A1 (en) 2016-05-24 2017-11-30 Indiana University Research And Technology Corporation Ku inhibitors and their use
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
EP3510027B1 (en) 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
KR102599339B1 (ko) * 2016-12-20 2023-11-08 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 화합물
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
WO2018187479A1 (en) * 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
CN110831593A (zh) * 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
WO2019040724A1 (en) * 2017-08-23 2019-02-28 The Regents Of The University Of Michigan SMALL MYC INHIBITOR MOLECULES AND USES THEREOF
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
WO2019101709A1 (en) 2017-11-23 2019-05-31 Universita' Degli Studi Di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
WO2019124577A1 (ko) * 2017-12-20 2019-06-27 재단법인 경기도경제과학진흥원 트리아졸 유도체 및 이의 용도
WO2019185736A1 (de) * 2018-03-29 2019-10-03 Explo Engineering Ag Vorrichtung und verfahren zur erzeugung von druckwellen hoher amplitude
GB201806004D0 (en) 2018-04-11 2018-05-23 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for TAU aggregates
WO2019209777A1 (en) * 2018-04-23 2019-10-31 The Curators Of The University Of Missouri Improved crispr therapy
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
US11299487B2 (en) * 2019-03-26 2022-04-12 Neuropore Therapies, Inc. Compounds and compositions as modulators of TLR signaling
US20230000982A1 (en) * 2019-09-25 2023-01-05 Korea Institute Of Radiological & Medical Sciences Composition for preventing or treating cancer, containing novel trifluoromethyl phenyl pyrazole derivative as active ingredient
KR102663365B1 (ko) * 2019-09-25 2024-05-08 한국원자력의학원 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
MX2022005766A (es) 2019-11-19 2022-08-08 Trevena Inc Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1).
WO2021119242A1 (en) * 2019-12-10 2021-06-17 The Trustees Of Indiana University Replication protein a (rpa)-dna interaction inhibitors
KR102847693B1 (ko) * 2019-12-27 2025-08-18 서울대학교산학협력단 옥사디아졸 유도체를 포함하는 비만의 예방 또는 치료용 조성물
EP3912628A1 (en) 2020-05-20 2021-11-24 Institut de Recherche en Semiochimie et Ethologie Appliquée Nucleoside analogues to inhibit the main protease of a coronavirus
WO2022168962A1 (ja) * 2021-02-04 2022-08-11 国立大学法人九州大学 Il-31産生抑制剤、及びそれを含有する医薬組成物
CN115594642B (zh) * 2021-06-28 2024-12-27 广西医科大学 阿齐瑞格三氮唑衍生物及其抗乳腺癌用途
EP4173485A1 (en) * 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein aggregation inhibiting compounds for plant disease control
KR20230140410A (ko) * 2022-03-25 2023-10-06 바스테라 주식회사 3-페닐이속사졸 유도체 및 이를 유효성분으로 함유하는 안질환 예방 또는 치료용 약학 조성물
JP2025540931A (ja) 2022-11-03 2025-12-17 セントニックス インコーポレイテッド タウ凝集体に対する選択的リガンド
GB202300021D0 (en) * 2023-01-03 2023-02-15 Thirtyfivebio Ltd Compounds
WO2025116596A1 (ko) * 2023-11-29 2025-06-05 가천대학교 산학협력단 신규 화합물 및 이를 포함하는 안질환 예방 또는 치료용 조성물
CN120987868A (zh) * 2024-08-08 2025-11-21 华药纪元(深圳)医药有限公司 一种五元并六元杂环化合物及其制备方法和应用
CN119144004B (zh) * 2024-08-12 2025-10-28 兰州大学 一种m-hof材料及其制备方法和在氢氧根离子识别中的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153017A (en) * 1961-06-29 1964-10-13 Eastman Kodak Co Nitrogen-containing linear polyesters from amino methyl cyclohexanol and dicarboxylic acids
CH489510A (de) 1967-02-07 1970-04-30 Geigy Ag J R Verfahren zur Herstellung von substituierten v-Triazolen
GB1263940A (en) 1968-08-02 1972-02-16 Innothera Lab Sa 0-phenyl-pyrroles
GB1248070A (en) * 1968-12-16 1971-09-29 Science Union & Cie Thiazolyl-benzoic acid derivatives and process for preparing them
US3803162A (en) 1969-10-03 1974-04-09 Sandoz Ltd 7-triazolyl-3-phenylcoumarins
US3679669A (en) 1970-09-23 1972-07-25 Ciba Geigy Ag Phenyl-1,3,4-oxdiazole compounds
US3882138A (en) * 1971-08-09 1975-05-06 Uniroyal Inc Oxazole and oxadiazole benzoic acid derivatives as herbicides
US3964896A (en) * 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
BE789948A (fr) 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3948937A (en) 1972-02-29 1976-04-06 E. I. Du Pont De Nemours And Company Pyrazole plant growth regulants
US4035175A (en) 1974-07-29 1977-07-12 Uniroyal Inc. Method of retarding the growth of plants using certain oxadiazolyl, oxazolyl or thiadiazolyl benzoic acid derivatives
US3947263A (en) 1974-07-29 1976-03-30 Uniroyal, Inc. Plant growth regulants
AU497898B2 (en) 1975-01-10 1979-01-18 Commonwealth Scientific And Industrial Research Organisation Plant growth regulating method and composition for use therein
US4038285A (en) * 1975-06-25 1977-07-26 E. I. Du Pont De Nemours And Company 1-(2-carboxyaryl)-4-arylimidazoles and 1-(2-carboxyaryl)-3-aryl-1,2,4-triazoles
US4032644A (en) 1975-12-29 1977-06-28 Sandoz, Inc. Isoxazolyl benzoic acids
DE2722331A1 (de) 1976-05-18 1977-11-24 Ricoh Kk 1,3,4-oxadiazolderivate sowie diese enthaltende elektrophotographische aufzeichnungsmaterialien
US4140515A (en) * 1977-05-12 1979-02-20 Monsanto Company Aryl-3-isoxazole benzoates as plant growth regulants and herbicides
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4268299A (en) * 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) * 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
CA1125768A (en) * 1978-10-31 1982-06-15 Hoffmann-La Roche Limited Benzoxazole derivatives
US4229204A (en) 1978-12-04 1980-10-21 Monsanto Company Trifluoromethylphenyl isoxazolyl benzoates
JPS58177977A (ja) 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd 4−フエニルピラゾ−ル類
SU1063100A1 (ru) * 1982-04-22 1985-06-30 Предприятие П/Я А-7850 Жидкокристаллический материал дл электрооптических устройств
US4760066A (en) * 1982-09-21 1988-07-26 Wayne State University Method for treating human tumor cell metastasis
US4546113A (en) * 1983-04-14 1985-10-08 Pfizer Inc. Antiprotozoal diamidines
DD226883A1 (de) * 1984-07-30 1985-09-04 Neubauer T Paedagog Hochschule Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
US5260451A (en) * 1989-05-11 1993-11-09 Merckle Gmbh Substituted pyrrole compounds and use thereof in pharmaceutical compositions
US5022915A (en) * 1990-03-01 1991-06-11 Ici Americas Inc. Substituted 2,4-diarylpyrimidines and their use as herbicides
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
FR2672050A1 (fr) 1991-01-30 1992-07-31 Atochem Diaryl-2,5 oxadiazoles-1,3,4 hydroxyester, hydroxyacide et acetoxyacide, leur procede de synthese.
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
IL112290A (en) * 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
WO1996011210A1 (en) * 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
DE19536811A1 (de) * 1995-10-02 1997-04-03 Basf Ag Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
KR100485642B1 (ko) 1996-03-18 2005-09-30 에자이 가부시키가이샤 축합고리함유카르복실산유도체
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
WO1998015532A1 (en) * 1996-10-09 1998-04-16 Novartis Ag Solid phase synthesis of heterocyclic compounds
KR20000069128A (ko) * 1996-11-25 2000-11-25 데이비드 엠 모이어 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노벤즈옥사졸 화합물
WO1998028421A1 (en) 1996-12-20 1998-07-02 Human Genome Sciences, Inc. Human oncogene induced secreted protein i
SI1023063T1 (en) * 1997-10-06 2004-02-29 Abbott Gmbh & Co. Kg INDENO(1,2-c), NAPHTHO(1,2-c)- AND BENZO(6,7)CYCLOHEPTA(1,2-c)PYRAZOLE DERIVATIVES
DE69818083T2 (de) * 1997-10-06 2004-07-08 Abbott Gmbh & Co. Kg INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
IT1300055B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
WO1999040108A1 (en) * 1998-02-09 1999-08-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
DE19904389A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
DE19904406A1 (de) 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolcarbonsäuren
DE60022386T2 (de) * 1999-12-16 2006-06-22 Schering Corp. Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
US7729756B2 (en) 2000-01-18 2010-06-01 Siemens Aktiengesellschaft Measurement system for examining a section of tissue on a patient and the use of a measurement system of this type
IL150987A0 (en) 2000-02-11 2003-02-12 Genentech Inc Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
AU2001245401A1 (en) * 2000-03-01 2001-09-12 Sumitomo Pharmaceuticals Company, Limited Hydrazones and analogs as cholesterol lowering agents
DZ3347A1 (fr) * 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
GB0012362D0 (en) 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
WO2002036580A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
PL369598A1 (en) * 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2446387A1 (en) 2001-05-09 2002-11-14 Sumitomo Chemical Takeda Agro Company, Limited Azole compound, process for producing the same and use thereof
JP2003026663A (ja) 2001-05-09 2003-01-29 Takeda Chem Ind Ltd アゾール化合物、その製造法および用途
EP1405636A4 (en) * 2001-06-26 2009-04-15 Takeda Pharmaceutical FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR
JP2003081832A (ja) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
DE10136066A1 (de) * 2001-07-25 2003-02-13 Bayer Cropscience Ag Tetrahydropyridazin-Derivate
US20070010562A1 (en) * 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
AU2002340010A1 (en) * 2001-09-26 2003-04-07 Bayer Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
EP1458708B1 (en) * 2001-12-18 2007-09-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
JP4286146B2 (ja) * 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤
JP4357965B2 (ja) 2001-12-21 2009-11-04 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピロールモジュレーター
US7229987B2 (en) * 2002-05-13 2007-06-12 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
WO2004009610A2 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
EP1525185A1 (en) * 2002-07-24 2005-04-27 PTC Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
EP1542667B1 (en) * 2002-07-24 2012-03-07 PTC Therapeutics, Inc. Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
CA2495285A1 (en) * 2002-08-13 2004-02-19 Merck Sharp & Dohme Limited Phenylpyridazine derivatives as ligands for gaba receptors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
JP2006501263A (ja) * 2002-09-09 2006-01-12 アムジエン・インコーポレーテツド 炎症治療用のTNF−αおよびインターロイキン低下剤としての1,4,5−置換1,2−ジヒドロ−ピラゾール−3−オンおよび3−アルコキシ−1H−ピラゾール誘導体
AU2003283597A1 (en) * 2002-11-16 2004-06-15 Oxford Glycosciences (Uk) Ltd Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
US20040176264A1 (en) * 2002-12-30 2004-09-09 The Procter & Gamble Company Rinse aid composition containing water-soluble metal salt for use in automatic dishwashing for glassware corrosion protection
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
ES2325440T3 (es) * 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
US7320986B2 (en) * 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US7226930B2 (en) 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
EP1784400B1 (en) 2004-08-23 2015-01-14 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
JP2008515992A (ja) * 2004-10-13 2008-05-15 ピーティーシー セラピューティクス,インコーポレーテッド 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
WO2007059356A2 (en) * 2005-11-19 2007-05-24 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
EP2284154A1 (en) * 2009-07-29 2011-02-16 Argon Pharma S.L. Antitumor 1,2-diphenylpyrrole compounds and their preparation process

Similar Documents

Publication Publication Date Title
JP2008515992A5 (cg-RX-API-DMAC10.html)
JP2008515985A5 (cg-RX-API-DMAC10.html)
ES2351183T3 (es) Composiciones farmacéuticas que contienen derivados de 3-amino-azetidina, nuevos derivados y su preparación.
AU2016299485B2 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
TW530046B (en) Azetidine derivatives, their preparation and medicaments containing them
US20210387957A1 (en) Bisphenol derivatives and their use as androgen receptor activity modulators
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
JP2011512412A5 (cg-RX-API-DMAC10.html)
JP2010524899A5 (cg-RX-API-DMAC10.html)
JP2013542267A5 (cg-RX-API-DMAC10.html)
JP2006525299A (ja) アゼチジンカルボキサミド誘導体及びcb1レセプター媒介障害の治療におけるその使用
JP2024510939A5 (cg-RX-API-DMAC10.html)
JPWO2023195529A5 (cg-RX-API-DMAC10.html)
CN1142153C (zh) 苯甲酰哒嗪
RU2007116987A (ru) Новые соединения
EP3548475B1 (en) Sulfonamide analogues of galiellalactone
KR20100098563A (ko) 아제티딘 유도체, 그의 제법 및 치료에서의 그의 적용
ES2248347T3 (es) Derivados de 2-aminotiazolina y su utilizacion como inhibidores de no-sintasa.
MX2024015833A (es) Compuesto bifuncional y composicion farmaceutica que comprende el compuesto bifuncional, y metodo para tratar enfermedades relacionadas con receptor de androgenos al usar el mismo
US10093609B2 (en) TAK1 kinase inhibitors, compositions, and uses related thereto
JP5497665B2 (ja) 2−アミノ−2−フェニル−アルカノール誘導体、それらの製造、及びそれらを含む医薬組成物
JP2011506393A5 (cg-RX-API-DMAC10.html)
CN102046620A (zh) 新的苯并噻吩氧化物衍生物及其盐
JP2022545181A5 (cg-RX-API-DMAC10.html)
JP2024512024A5 (cg-RX-API-DMAC10.html)